Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027
Open the sourceReported by Seeking Alpha, seekingalpha.com, 6 November 2026
Not scored
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at seekingalpha.com.